Form 8-K - Current report:
SEC Accession No. 0001193125-24-272559
Filing Date
2024-12-06
Accepted
2024-12-06 17:19:30
Documents
18
Period of Report
2024-12-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916273d8k.htm   iXBRL 8-K 35458
2 EX-99.1 d916273dex991.htm EX-99.1 15009
3 EX-99.2 d916273dex992.htm EX-99.2 28936
7 GRAPHIC g916273g1206225109324.jpg GRAPHIC 21689
8 GRAPHIC g916273g1206225109624.jpg GRAPHIC 20838
9 GRAPHIC g916273g1206225335269.jpg GRAPHIC 2586
  Complete submission text file 0001193125-24-272559.txt   284489

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA stok-20241204.xsd EX-101.SCH 2881
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20241204_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20241204_pre.xml EX-101.PRE 11279
20 EXTRACTED XBRL INSTANCE DOCUMENT d916273d8k_htm.xml XML 3627
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 241533232
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)